Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Indication
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Section

Indication

1 evidence topic · 1 source

“Praxis has submitted an NDA for relutrigine for the treatment of SCN2A and SCN8A DEEs” (opens the source at this quote in a new tab)